The role of EGFR in KRASG12D-driven tumorigenesis was studied using mouse CRC organoids with KRAS-APC-TP53 mutations and ...

Why then would most of the crystallized forms of EGFR show the receptor in its active conformation? Most likely, the crystallization process necessary for analyzing protein structure caused a high ...

Tonelli believes that those with a family history of the illness will ... successfully inhibit FGFR2, plus the EGFR protein — it is known to accelerate pancreatic cancer — she observed slower ...

One in four dogs will get cancer at some point during their lifetime, and sometimes there aren't a lot of options for ...

RxDx assay as a companion diagnostic to identify c-Met protein expression in non-squamous NSCLC patients eligible for treatment with Emrelis.

A new study from Cold Spring Harbor Laboratory, published in Cancer Research, shows that inhibiting the FGFR2 and EGFR proteins in pancreatic cells can delay or even prevent tumor formation.

C-Met is a cell surface protein that is overexpressed in approximately 25% of patients with advanced epidermal growth factor receptor (EGFR) wild-type, nonsquamous NSCLC, driving tumor progression.

EGFR and HER3 are members of the human epidermal growth factor receptor (HER) family and are validated ... Somatostatin receptor 2 (SSTR2) is a G protein-coupled receptor (GPCR) that is ...